(NP (NP (NP (NN Drug) (NNS Names)) (, ,) (NP (NNP Population) (NNP Level) (NNP Surveillance)) (CC and) (NP (NP (DT the) (NNP FDA) (POS 's)) (JJ Adverse) (NN Event))) (VP (VBG Reporting) (NP (NP (NN System)) (: :) (NP (NP (DT An) (JJ Exploratory) (NNP Data) (NNP Survey)) (PP (IN of) (NP (NML (NNP Drug) (NNP Name)) (NML (NML (NN Incidence) (CC and) (NN Prevalence)) (, ,) (NP (CD 2004) (HYPH -) (NN 2012Q2))) (NN Purpose)))) (: :)) (S (VP (TO To) (VP (VB count) (CC and) (VB monitor) (NP (NP (DT the) (NN drug) (NNS names)) (VP (VBN reported) (PP (IN in) (NP (NP (DT the) (ADJP (RB publicly) (JJ available)) (NN version)) (PP (IN of) (NP (DT the) (NNP Federal) (JJ Adverse) (NN Event))))) (S (VP (VBG Reporting) (NP (NNP System) (-LRB- -LRB-) (NNP FAERS) (-RRB- -RRB-)) (PP (IN from) (NP (CD 2004))) (PP (IN to) (NP (NP (NN 2012Q2)) (PP (IN in) (NP (DT a) (VBN maximized) (NN sensitivity) (JJ relational) (NN model))))))))))))) (. .))
(FRAG (NP (NNS Methods)) (: :) (NP (NP (NNS Data)) (SBAR (S (S (NP (NML (NN mining) (CC and) (NNS data)) (NN modeling)) (VP (VBD was) (VP (VBN conducted)))) (CC and) (S (NP (NP (ADJP (NN event) (VBN based)) (NN summary) (NNS statistics)) (PP (IN with) (NP (NNS plots)))) (VP (VBD were) (VP (VBN created) (PP (IN from) (PP (IN over) (NP (NP (CD nine) (JJ continuous) (NNS years)) (PP (IN of) (NP (JJ continuous) (NN FAERS) (NNS data)))))))))))) (. .))
(FRAG (NP (NNS Results)) (: :) (S (NP (DT This) (JJ FAERS) (NN model)) (VP (VBZ contains) (NP (NP (NP (CD 344,452) (JJ individual) (NN drug) (NNS names)) (CC and) (NP (CD 432,541,994) (NN count) (NNS references))) (SBAR (WHNP (WDT which)) (S (VP (VBD occurred) (PP (IN across) (NP (NP (CD 4,148,761) (JJ human) (NNS subjects)) (PP (IN in) (NP (DT the) (NML (CD 34) (NN quarter)) (NN study) (NN period))))))))))) (. .))
(S (S (NP (NP (NNS Plots)) (PP (IN for) (NP (NP (DT the) (JJ top) (CD 100)) (VP (VBG scoring) (NP (NN drug) (NN name) (NNS references)))))) (VP (VBP are) (VP (VBN reported) (PP (IN by) (NP (NN year) (CC and) (NN quarter)))))) (: ;) (S (NP (DT the) (JJ top) (NML (CD 100) (NN drug)) (NNS names)) (VP (VBP contain) (NP (NP (CD 143,384,240) (NNS references)) (CC or) (NP (NP (CD 33) (NN %)) (PP (IN of) (NP (DT all) (NN drug) (NN name) (NNS references))))) (PP (IN over) (NP (NP (CD 34) (NNS quarters)) (PP (IN of) (NP (JJ continuous) (NN FAERS) (NNS data))))))) (. .))
(FRAG (NP (NNS Conclusions)) (: :) (S (SBAR (IN While) (S (NP (NN FAERS)) (VP (VBZ contains) (NP (NP (JJ many) (NNS drugs)) (CC and) (NP (JJ adverse) (NN event) (NNS reports)))))) (, ,) (NP (PRP$ its) (NNS data)) (VP (VBZ pertains) (PP (IN to) (NP (NP (ADJP (RB very) (JJ few))) (PP (IN of) (NP (PRP them))))))) (. .))
(S (NP (NN Drug) (NN name) (NN incidence)) (VP (VP (VBZ lends) (NP (NP (ADJP (JJ timely) (CC and) (JJ effective)) (NN surveillance)) (PP (IN of) (NP (NP (JJ large) (NNS populations)) (PP (IN of) (NP (JJ Averse) (NN Event) (NNS Reports))))))) (CC and) (VP (VBZ does) (RB not) (VP (VB require) (NP (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NN AE)))) (, ,) (CC nor) (NP (PRP$ its) (NN validity) (S (VP (TO to) (VP (VB be) (VP (VBN known) (S (VP (TO to) (VP (VB detect) (NP (DT a) (NN mass) (NN poisoning)))))))))))))) (. .))
